The Hindu Business Line : Zydus gets USFDA nod for Warfarin

Zydus Cadila has received approval from the US Food and Drug Administration (USFDA) to market Warfarin tablets in different strengths and the Group plans to launch the product within a month, according to a company release. The potencies of the drug would range from one mg to 10 mg. The branded sales of the product, an anti-coagulant falling in the cardiovascular segment, in 2005 was reported to be more than $210 million . With the Warfarin approval, the Zydus Cadila Group now has a total of 14 approvals. The Group is likely to have competitive advantage in this product as it will be sourcing the API from its own USFDA-approved manufacturing facility at Dabhasa, the release added.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Baring India sells its entire stake in Mphasis to EDS

ICAI plans major brand-building exercise

GE Shipping de-merger plan may go off course

Numaligarh Refinery equity recast approved

Punj Lloyd acquires construction firm in Singapore for Rs 100 cr

Crompton to buy 59 pc stake in MCPPL

TIDCO's stake set to fall in SPIC

ITC goes for integrated hotel complex in Chennai

Jindal Steel bags development rights for Bolivian iron ore mine

Zydus gets USFDA nod for Warfarin

Nissan to tap Maruti facilities

EuroCOR gets CE okay for products

Wockhardt scales down biotech revenue projection

Max Healthcare to invest Rs 250 cr in expansion

Tata Motors vehicle sales up 45% in May

B.K. Sinha takes over as SECL CMD

Ramesh Suri is Chelmsford Club Chairman